{"entity":{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","aka":[],"tldr":"Hatem Soliman is a breast oncologist leading immunotherapy and genomic-assay trials, including in triple-negative disease.","summary":"Hatem Soliman is Medical Director of the Clinical Trials Office and a breast oncologist at Moffitt Cancer Center. He is known for leading immunotherapy and genomic-assay trials in breast cancer, including in triple-negative disease, and for work validating breast genomic classifiers. His selected paper reports a phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer. He now runs Moffitt's clinical trials office and continues as an investigator in triple-negative and hormone receptor-positive breast cancer studies.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/hatem-soliman/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soliman%20H%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Medical Director, Clinical Trials Office; Breast Oncology","institutionId":"moffitt","specialisms":["Breast cancer","Immunotherapy","Genomic assays"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/hatem-soliman/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soliman%20H%5BAuthor%5D"}],"papers":[{"title":"A phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer","journal":"Cancer Immunology Research","year":2018}],"orcid":"0000-0001-6644-2264"},"route":"/people/hatem-soliman/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"institution":[{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/"}],"journal":[{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/"}]}}